NCT04271007 (LB2001) is a Phase 4 clinical trial of Mometasone Furoate in Atopic Dermatitis, sponsored by Libbs Farmacêutica LTDA.

Who is sponsoring NCT04271007?

NCT04271007 is sponsored by Libbs Farmacêutica LTDA.

What drugs are being tested in NCT04271007?

Interventions in NCT04271007: Mometasone Furoate.

What condition does NCT04271007 study?

NCT04271007 studies Atopic Dermatitis.

Is NCT04271007 still recruiting?

NCT04271007 is currently completed. Last updated 11 October 2023.

Last reviewed 2023-10-11 · How we verify

NCT04271007: LB2001

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparative Study:Topison (Mometasone Furoate) Versus Two Others Mometasone Furoates

Completed Phase 4 Last updated 11 October 2023

What this trial tests

Phase 4 trial testing Mometasone Furoate in Atopic Dermatitis in 32 participants. Completed in 10 July 2023.

Timeline

23 November 2020

Primary endpoint
10 July 2023

10 July 2023

Quick facts

Lead sponsor	Libbs Farmacêutica LTDA
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	other
Enrollment	32
Start date	23 November 2020
Primary completion	10 July 2023
Estimated completion	10 July 2023
Sites	1 location across Brazil

Drugs / interventions tested

Mometasone Furoate (MOMETASONE FUROATE) — full drug profile →

Conditions studied

Atopic Dermatitis — all drugs for Atopic Dermatitis →

Sponsor

Libbs Farmacêutica LTDA

Who can join

Adults 10 to 60, any sex, with Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Atopic dermatitis is a chronic disease, with outbreaks, predominant in childhood, whose main symptom is pruritus of variable intensity and signs of cutaneous xerosis and eczematous pattern lesions. In this context, the present study aims to evaluate a comparative way of Topison drugs in reducing transepidermal water loss, improving skin hydration and comfort in participants with atopic dermatitis.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Strategies for using topical corticosteroids in children and adults with eczema.
Lax SJ, Harvey J, Axon E, Howells L, et al · · 2022 · cited 38× · PMID 35275399 · DOI 10.1002/14651858.cd013356.pub2
Clinical Measurement of Transepidermal Water Loss.
Kundu D, Jayaraman A, Sen CK. · · 2026 · cited 4× · PMID 40476522 · DOI 10.1089/wound.2024.0148

Verify or expand the search:

Other trials of Mometasone Furoate

Trials testing the same drug.

NCT06399783 — Topical Simvastatin Versus Topical Steroid in Treatment of Alopecia Areata · Phase 4 · not yet recruiting
NCT05887843 — Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and · Phase 1 · terminated
NCT04898764 — Research on Underlying Causes of Long-term Use of Nasal Decongestants and the Structured Withdrawal of the Decongestant · Phase 4 · completed
NCT04532736 — Comparison of Methylprednisolone or Methotrexate in the Maintenance Treatment of Nasal Polyposis · Phase 2 · completed

Other recruiting trials for Atopic Dermatitis

Currently open trials in the same condition.

NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi · Phase 1 · recruiting
NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis · Phase 2 · recruiting
NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants · Phase 1 · recruiting
NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting

Other Libbs Farmacêutica LTDA trials

Trials by the same sponsor.

NCT06808685 — Real World Multicenter National Study to Evaluate the Effectiveness and Safety of Biosimilar Bevacizumab Elovie · recruiting
NCT04928573 — Study for Late Assessment of the Safety and Efficacy of Biosimilar Rituximab · completed
NCT05040672 — Evaluation of Knowledge and Practice About Prostate Cancer in Male Employees · completed
NCT04373863 — Assessment of Lifestyle, Blood Pressure, Cholesterol and Glycated Hemoglobin in a Specific Population · completed
NCT04455685 — Prevalence of Self-reported Premenstrual Syndrome and Analysis of Somatic and Psychoemotional Symptoms · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04271007 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Libbs Farmacêutica LTDA
Last refreshed: 11 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04271007.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing